Zevra Therapeutics, Inc. ZVRA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.89M+211% | $12.17M+2,336% | -$544K-101% | $74.71M+2,511% | -$3.1M+91.3% | ||
| $368K+1.7% | $362K-7.7% | $392K-76.3% | $1.65M+0.1% | $1.65M+0.1% | ||
| $3.11M-27.5% | $4.28M+54.6% | $2.77M+12.5% | $2.46M-20.9% | $3.12M-22.5% | ||
| $43.31M— | —— | —— | —— | $0— | ||
| $185K-64.8% | $525K+171% | $194K-49.1% | $381K+85.9% | $205K-95.7% | ||
| -$529K— | $0+100% | -$4.73M-18.1% | -$4M+44.9% | -$7.27M— | ||
| -$2.05M+45.9% | -$3.79M-225% | $3.05M+423% | $582K+303% | -$286K— | ||
| $416K+107% | -$5.98M-311% | $2.83M+97.9% | $1.43M+156% | $560K-70.0% | ||
| $341K— | —— | —— | —— | $663K— | ||
| $118K— | —— | —— | —— | $0-100% | ||
| -$2.76M— | —— | —— | —— | $0— | ||
| -$123K+4.7% | -$129K+90.0% | -$1.29M-238% | $936K+593% | -$190K+17.7% | ||
| -$6.89M-208% | $6.37M— | —— | $4.86M+131% | $2.11M— | ||
| $6.14M— | —— | —— | -$3.6M+56.2% | -$8.22M+49.4% | ||
| $35K— | $0-100% | $554K+160% | $213K+115% | $99K— | ||
| $58.3M-33.1% | $87.16M+33.9% | $65.11M-56.7% | $150.35M+1,943% | $7.36M-82.1% | ||
| $93.97M+7.4% | $87.5M+44.6% | $60.5M+384% | $12.5M-30.6% | $18M+8,811% | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $42K— | —— | —— | —— | $0— | ||
| $43.94M— | —— | —— | —— | $0— | ||
| $79.62M+34,974% | $227K— | —— | $11.93M+13.2% | $10.54M+293% | ||
| $60.09M— | $0— | $0— | $0— | $0— | ||
| $752K— | $0+100% | -$2.95M-200% | $2.95M— | $0— | ||
| $2.64M— | —— | —— | —— | —— | ||
| -$52.8M-2,174% | $2.55M-61.0% | $6.53M+373% | $1.38M-14.1% | $1.61M+102% | ||
| $233K— | —— | $64K-90.3% | $658K+277% | -$372K-155% | ||
| $33.19M+317% | $7.97M+18.4% | $6.73M-35.1% | $10.37M+192% | $3.56M+118% | ||
| $1.37M+2.5% | $1.34M-2.1% | $1.37M+3.5% | $1.32M+1.1% | $1.31M-18.1% | ||
| $624K-27.2% | $857K-29.2% | $1.21M+60.4% | $755K+148% | $305K-65.7% | ||
| $9.02M— | —— | —— | —— | $0— | ||
| $0— | —— | —— | —— | $75K0.0% | ||
| $1.15M— | —— | $1.47M+29.3% | $1.14M-40.6% | $1.91M— | ||
| $216K+820% | -$30K+75.8% | -$124K-6,300% | $2K-33.3% | $3K-96.3% | ||
| -$7.22M— | —— | —— | —— | $0— | ||
| -$968K+72.8% | -$3.56M-165% | $5.51M+637% | $747K+115% | -$4.87M— | ||
| $1.4M+199% | -$1.42M— | —— | —— | -$213K-196% | ||
| $6.91M+1,280% | $501K— | —— | $2.2M+86.0% | $1.18M-92.3% | ||
| -$6.89M-208% | $6.37M— | —— | $4.86M+131% | $2.11M— | ||
| -$123K+4.7% | -$129K+90.0% | -$1.29M-238% | $936K+593% | -$190K+17.7% | ||
| $0— | —— | -$1.27M-232% | $964K+681% | -$166K— | ||
| $416K+107% | -$5.98M-311% | $2.83M+97.9% | $1.43M+156% | $560K-70.0% | ||
| $87K— | —— | —— | —— | $0— | ||
| -$2.05M— | —— | $3.05M+423% | $582K+303% | -$286K-116% | ||
| -$4.39M— | —— | —— | —— | $0— | ||
| $485K— | $0— | $0-100% | $11.7M— | $0-100% | ||
| $118K— | —— | —— | —— | $0-100% | ||
| $3.13M— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| $58.3M-33.1% | $87.16M+33.9% | $65.11M-56.7% | $150.35M+1,943% | $7.36M— | ||
| $93.97M+7.4% | $87.5M+44.6% | $60.5M+384% | $12.5M-30.6% | $18M+8,811% | ||
| $42K— | —— | —— | —— | $0— | ||
| $0— | —— | —— | —— | $372K— | ||
| $752K— | —— | —— | —— | $1.98M— | ||
| $9.17M+242% | $2.68M— | —— | —— | $0— | ||
| $60.09M— | $0— | $0— | $0— | $0— | ||
| $233K— | —— | $64K-90.3% | $658K+277% | -$372K-155% | ||
| -$123K+4.7% | -$129K+90.0% | -$1.29M-238% | $936K+593% | -$190K+17.7% | ||
| $0— | —— | —— | —— | $1.12M— | ||
| $5M— | —— | —— | —— | $0— | ||
| $6.11M— | —— | —— | -$3.81M+54.2% | -$8.32M+48.8% | ||
| $6.11M— | —— | —— | -$3.81M+54.2% | -$8.32M+48.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Zevra Therapeutics, Inc. generate?
- Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
- Where does Zevra Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
